21-Oct-2026 13:34:28
BHARAT PARENTERALS : SUBSIDIARY INNOXEL COMMENCES US COMMERCIAL SUPPLY
• Innoxel Lifesciences (55.9% subsidiary) launched its first CMO product in the U.S. market through its sponsor partner on October 20, 2026 • Product manufactured at Innoxel's finished dosage facility in Vadodara, which received a U.S. FDA EIR in July 2025 and an EU-GMP certificate covering all four lines in March 2026 • Launch is the first of two CMO products the company expects to commercialise in FY27 • Revenue mix shifts: Innoxel's entire FY26 revenue of ₹72.4 Cr was licensing (₹17.1 Cr upfront, ₹55.3 Cr milestone-linked); commercial supply adds a recurring per-batch line • Innoxel signed 23 deals in FY26 (seven out-licensing, sixteen CMO/CDO), taking the total since inception to 48, with 19 active partners (8 US, 6 EU, 5 India)
Bharat Parenterals Ltd
Open attachment